论文部分内容阅读
目的:探讨不同剂量及途径给药的EP方案对非小细胞肺癌的疗效及不良反应。方法:1998年3月-2000年5月将156例非小细胞肺癌患者随机分为A(40例)、B(36例)、C(42例)、D(38例)4组,并分别予静脉滴注大剂量顺铂加口服足叶乙甙或静脉滴注足叶乙甙,以及静脉滴注小剂量顺铂加口服足叶乙甙或静脉滴注足叶乙甙组成的EP方案治疗。结果:4种EP方案的有效率分别为45%(18/40)、47.22%(17/36)、45.24%(19/42)47.37%(18/38);中位缓解期分别为4月、4.2月、3.8月、3.5月,经统计学分析均无明显差异(P>0.05)。但其不良反应有明显差别(P<0.05),C组出现白细胞下降、恶心呕吐及脱发反应最少,B组最多。结论:静脉滴注小剂量顺铂加口服足叶乙甙组成的EP方案给药方法简便,不良反应少,而且经济,比较适合年老体弱及经济落后地区非小细胞肺癌患者的姑息性治疗。
OBJECTIVE: To investigate the efficacy and adverse reactions of EP regimen with different dosage and route of administration on non-small cell lung cancer. Methods: From March 1998 to May 2000, 156 patients with non-small cell lung cancer were randomly divided into A (40 cases), B (36 cases), C (42 cases) and D (38 cases) Intravenous infusion of large doses of cisplatin plus etoposide or intravenous infusion of etoposide, and intravenous infusion of low-dose cisplatin plus oral etoposide or intravenous infusion of etoposide EP regimen composition . Results: The efficacy rates of the four EP regimens were 45% (18/40), 47.22% (17/36) and 45.24% (19/42), respectively. The median response time was 47.37% (18/38) , 4.2 months, 3.8 months, 3.5 months, no statistically significant differences (P> 0.05). However, there was a significant difference in adverse reactions (P <0.05). Leukopenia, nausea, vomiting and hair loss were the least in group C, with the most in group B. Conclusion: The EP regimen consisting of intravenous infusion of low-dose cisplatin plus etoposide is simple and convenient, with few adverse reactions, and is economical. It is suitable for palliative treatment of non-small cell lung cancer in the elderly and infirm areas .